Atlas Trials

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

Clinical trial NCT03086343 · COMPLETED

Trial details

NCT number
NCT03086343
Sponsor
AbbVie
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Rheumatoid Arthritis (RA)
Start date
2017-05-09
Primary completion
2019-06-13
Enrollment
657

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.